vioxx rofecoxib

Medical Beat
New drug to treat major depression. ( www.fda.gov ) - The Food and Drug Administration today approved Emsam (selegiline), the first skin (transdermal) patch for use in treating major depression.
Source: www.baynews9.com

Benedictine College Discovery Day Speaker Focuses on Ethics, Drugs, and the FDA
Dr. David J. Graham, best known for his research leading to the removal of such drugs as Fen-Phen, Rezulin and Vioxx from the market, will be the keynote speaker for Benedictine College's signature Discovery Day event. [PRWEB Mar 27, 2006] Trackback URI: http://www.prweb.com/zingpr.php/VGhpci1UaGlyLU1hZ24tVGhpci1IYWxmLVplcm8=
Source: www.prweb.com

New advertising code of conduct established in Vioxx withdrawal fallout
Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising. As more and more drugs are likely to come under regulatory and public scrutiny, the pharmaceutical industry will need to employ effective marketing and education strategies to ensure patient and physician confidence is retained and the impact of drug safety scares is minimized.
Source: www.pharmaceutical-business-review.com

Thomson Scientific Names 'Red-Hot' Research Papers of 2005
The New England Journal of Medicine leads the pack in this year's 'Red-Hot Research Papers' rankings by publishing the most-cited research paper of 2005. This, according to the March/April issue of Science Watch - the bimonthly newsletter published by Thomson Scientific, a business unit of The Thomson Corporation.
Source: sys-con.com

Where the money is
It was US investors that largely bankrolled the biotech industry over the past 25 years. Is all that about to change? Michael Fitzgerald investigates.
Source: www.nature.com

Thomson Scientific Names 'Red-Hot' Research Papers of 2005
PHILADELPHIA and LONDON, March 20 /PRNewswire-FirstCall/ -- The New England Journal of Medicine leads the pack in this year's "Red-Hot Research Papers" rankings by publishing the most-cited research paper of 2005.
Source: www.redorbit.com

The USA is the World's Largest and Wealthiest Pharmaceutical Market, Accounting for Around 48% of the World Total with
DUBLIN, Ireland----March 6, 2006--Research and Markets has announced the addition of Espicom's "The Outlook for Pharmaceuticals: USA" to their offering.
Source: biz.yahoo.com

24 March 2006
Resources | Features | New advertising code of conduct est... Recent high-profile drug withdrawals have resulted in a new code of conduct to govern direct-to-consumer advertising.
Source: www.pharmiweb.com

Study finds Celebrex doubles heart attack risk
Pharma Times (subscription), UK - Mar 1, 2006... March 2006), suggest that the increased risk of cardiovascular side effects that led to the withdrawal of Merck & Co's similar drug Vioxx (rofecoxib) may be a ...
Source: www.pharmatimes.com

The USA is the World's Largest and Wealthiest Pharmaceutical ...
Business Wire (press release), CA - Mar 6, 2006... The question of drug safety has come under intense scrutiny following the September 2004 withdrawal of Vioxx (rofecoxib) from the market. ...
Source: home.businesswire.com

Arthritis drug increases risk of heart attacks: study
Stuff.co.nz, New Zealand - Feb 28, 2006... Rofecoxib, also a COX-2 inhibitor drug, was manufactured by drug company Merck under the name Vioxx but voluntarily withdrawn worldwide following evidence ...
Source: www.stuff.co.nz

Man claims heart attack from taking Vioxx
St. Clair Record, IL - Mar 6, 2006... Vioxx, which was removed from the drug market on Sept. 30, 2004, because a study indicated it could cause cardiac problems, is the brand name of rofecoxib, a ...
Source: www.stclairrecord.com